It probably doesn't hurt to have people like that on your board when you go looking for funding.
Being on a corporate board has got to be the easiest job in the world. When things are going well you collect a six or seven figure paycheck for doing almost nothing.
It's hard for me to imagine they wouldn't have said "well, one drop didn't work but we could decently with four but we won't do that."
I haven't followed tremendously the story though.
The second problem with fingerprick blood is you pick up quite a bit of skin tissue in the process, but the amount collected is quite variable. What you end up measuring is blood + some unknown percentage of skin tissue derived material. None of these things are good for reproducibility.
Hanlon's razor isn't proof of anything.
That said, Hanlon's razor can't explain away evidence.
if (benefit > 0) {
P(malice) >> P(stupidity)
}
It seems more likely they were very close on the science, and decided to run with it while they worked out the last 10%. That works great for most tech companies, but healthcare technology is very different.